Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
One-third of patients with rare endocrine and neuroendocrine neoplasms who underwent CGP had a druggable alteration and received a treatment recommendation from the MTB. However, only 28.6% of these patients were treated accordingly. Our experience highlights the unmet medical need for targeted treatment options in patients with rare cancers.
Authors
- Ralf Schmidmaier (ORCID: https://orcid.org/0000-0003-3541-3588)
- Lena Weiss (ORCID: https://orcid.org/0000-0002-8101-3529)
- Martin K. Angele (ORCID: https://orcid.org/0000-0003-0565-7688)
- Martín Reincke (ORCID: https://orcid.org/0000-0002-9817-9875)
- Michael von Bergwelt‐Baildon (ORCID: https://orcid.org/0000-0002-1952-052X)
- Christoph Josef Auernhammer (ORCID: https://orcid.org/0000-0001-8087-3722)
- Christine Schmid‐Tannwald (ORCID: https://orcid.org/0000-0002-7304-6961)
- Matthias Kroiß (ORCID: https://orcid.org/0000-0002-7628-3161)
- C. Benedikt Westphalen (ORCID: https://orcid.org/0000-0002-5310-3754)
- Amanda Tufman (ORCID: https://orcid.org/0000-0001-9243-9050)
- Danmei Zhang (ORCID: https://orcid.org/0000-0001-6048-4711)
- Frederick Klauschen (ORCID: https://orcid.org/0000-0002-9131-2389)
- Jörg Kumbrink (ORCID: https://orcid.org/0000-0003-4633-4105)
- Kathrin Heinrich (ORCID: https://orcid.org/0000-0003-3580-2313)
- Christine Spitzweg (ORCID: https://orcid.org/0000-0002-0413-9697)
- Thomas Knösel (ORCID: https://orcid.org/0000-0002-1822-0197)
- Klara Dorman (ORCID: https://orcid.org/0000-0003-2503-5851)
- Svenja Nölting (ORCID: https://orcid.org/0000-0002-7064-590X)
- Christian Schulz (ORCID: https://orcid.org/0000-0002-5615-2113)
- Andreas Jung
- Josefine Rauch
- Mathias J. Zacherl
- Jens Werner
- Stefan Böck
- Volker Heinemann
Institutions
- German Cancer Research Center (DE)
- LMU Klinikum (DE)
- European Neuroendocrine Tumor Society (DE)
- University Hospital of Zurich (CH)
- München Klinik Neuperlach (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Targeted Oncology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1007/s11523-025-01152-6
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35